In patients with nondialysis CKD, the serum potassium pattern in the previous 12 months is prognostic for major adverse events.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection and may lower the risk for hyperkalemia.
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Hyperkalemia signals diminished kidney function and lasting risks to kidney health, according to investigators.
Patient with and without diabetes who received patiromer were more likely to remain on spironolactone at 12 weeks compared with those who received placebo, a subgroup analysis of the AMBER trial showed.
How much do your patients know about the dangers of high potassium levels in the body? They may know that potassium is good for you, or that you need specific levels of it in the blood, but they may not know the effects of high potassium, or hyperkalemia. As their healthcare professional, how can you educate them on the dangers of hyperkalemia?
Investigators reviewed 13 trials of spironolactone and 1 trial of eplerenone.
Appropriate treatment for hyperkalemia might be a key factor to improving renal outcome in patients with CKD, according to investigators.
Even a single episode of hyperkalemia is associated with a major disease burden, a study finds.
Nearly two-thirds of inpatients with a hyperkalemia diagnosis do not receive potassium binders, according to a contemporary analysis.